Another Drugmaker to Cut Insulin Costs
Novo Nordisk has announced it will begin slashing U.S. insulin prices up to 75% next year, mirroring a similar move being made by Eli Lilly earlier. The Danish drugmaker, which manufactures pre-filled pens and vials of long- and short-acting insulins, listed Levemir, Novolin, NovoLog and NovoLog Mix 70/30 as the products to see price reductions, set to take effect in January of 2024. As one example, the list price for NovoLog Mix 70/30 will drop to just over $72 from almost $290 currently. List prices are what a drugmaker initially sets for a product and what people without insurance or other benefits can end up paying.
Did you find our information helpful?
We are always adding new information and resources and are open to suggestions for improvement. We can do even more with your contributions.